RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsMay 21, 2024 - "AstraZeneca counts on ‘difficult-to-copy’ therapies for big 2030 goal and beyond"
'At the drugmaker’s Discovery Centre in Cambridge, UK, the CEO, self-assured as ever, underscored his vision for “long-term growth” by centering certain drug modalities that could be less vulnerable to generic and biosimilar competition.'
https://endpts.com/astrazeneca-outlines-growth-plans-for-2030-and-beyond-with-focus-on-difficult-to-copy-therapies/